1. 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. (September 2015) Authors: Long, G.V.; Dummer, R.; Ribas, A.; Puzanov, I.; Michielin, O.; Vanderwalde, A.; Andtbacka, R.H.I.; Cebon, J.; Fernandez, E.; Malvehy, J.; Olszanski, A.J.; Gajewski, T.F.; Kirkwood, J.M.; Gause, C.; Chen, L.; Kaufman, D.R.; Chou, J.; Hodi, F.S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S722 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3330 Clinical benefits associated with durable response (DR) in patients (pts) with unresected stage IIIB/C/IV melanoma treated with talimogene laherparepvec (T-VEC) or GM-CSF in the randomized phase 3 OPTiM trial (NCT00769704). (September 2015) Authors: Kaufman, H.L.; Andtbacka, R.H.I.; Collichio, F.A.; Wolf, M.; Li, A.; Shilkrut, M.; Murugappan, S.; Zhao, Z.; Puzanov, I.; Ross, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S674 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3334 Durable complete responses (CR) in patients (pts) with stage IIIB-IV melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. (September 2015) Authors: Andtbacka, R.H.I.; Kaufman, H.; Collichio, F.; Amatruda, T.; Nemunaitis, J.; Chesney, J.; Puzanov, I.; Harrington, K.; Zhang, Y.; Chen, L.; Shilkrut, M.; Ross, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3335 Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses. (September 2015) Authors: Andtbacka, R.H.I.; Curti, B.; Kaufman, H.L.; Daniels, G.A.; Nemunaitis, J.J.; Spitler, L.E.; Hallmeyer, S.; Lutzky, J.; Schultz, S.; Whitman, E.D.; Zhou, K.; Karpathy, R.; Weisberg, J.I.; Shafren, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3336 Phase II CALM extension study: Enhanced immune-cell infiltration within the tumour micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21. (September 2015) Authors: Andtbacka, R.H.I.; Curti, B.; Hallmeyer, S.; Feng, Z.; Paustian, C.; Bifulco, C.; Fox, B.; Grose, M.; Davies, B.; Karpathy, R.; Shafren, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S677 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗